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Abstract
Following the discovery of synergistic action between oxacillin and manuka honey against methicillin-resistant
Staphylococcus aureus, this study was undertaken to search for further synergistic combinations of antibiotics and honey
that might have potential in treating wounds. Fifteen antibiotics were tested with and without sublethal concentrations of
manuka honey against each of MRSA and Pseudomonas aeruginosa using disc diffusion, broth dilution, E strip,
chequerboard titration and growth curves. Five novel antibiotic and manuka honey combinations were found that
improved antibacterial effectiveness in vitro and these offer a new avenue of future topical treatments for wound infections
caused by these two important pathogens.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomo-
nas aeruginosa (P. aeruginosa) are important nosocomial pathogens
that cause serious infections with significant associated morbidity
and mortality, especially in people with weakened immune
systems. Both have been implicated in wound infection and
management of infections has been complicated by the emergence
and continued prevalence of multiple drug resistant (MDR) strains
with resistance determinants to antibiotics of several different
classes [1,2]. The problem of finding effective treatments has been
delayed by reduced investment in the discovery and development
of new antibiotics.
Substantial efforts to find effective therapies by combining
different antibiotics have been made in the treatment of MDR
infections such as tuberculosis. Combination therapy has been
promoted as a strategy for reducing the emergence of antibiotic
resistant strains because the use of two or more antimicrobials with
differing modes of action decreases the likelihood of an organism
possessing the traits necessary to survive [3]. An advantage of
combination therapy is that less of each antimicrobial agent needs
to be administered, thus reducing treatment costs and the
possibility of side effects. Using synergistic combinations of
antimicrobial agents provides a means to achieve greater efficacy
than that expected by combining the two non-synergistic agents.
Natural products that have shown potential for future use with
current antibiotics include gallocatechins, Saliva miltiorrhiza and
curcuminoids [4–6]. Honey is another possible candidate for
synergistic action with antibiotics. The first report of synergistic
action between an Indian honey and antibiotics against MDR
bacteria isolated from clinical specimens was in 1998 [7].
Combinations of honey and each of gentamicin, amikacin and
ceftazidime tested by broth dilution were shown to act synergis-
tically in inhibiting six strains of P. aeruginosa but not eight Klebsiella
strains. One Omani honey selected from 30 samples was shown to
enhance the activity of gentamicin against Staphylococcus aureus by
22% within 30 minutes [8]. Neither of these studies deduced
numerical values to support their deductions of synergy.
Although an ancient topical treatment for wounds, honey has
been re-accepted into conventional medicine and it is currently
available as a licensed medical device either incorporated into
sterile dressings or sterilised in tubes. Manuka honey is one of the
medical grade honeys available that is used in these formulations.
It has been shown to inhibit the growth of many organisms in vitro
including S. aureus [9] and P. aeruginosa [10] and can eradicate
bacteria from colonised wounds [11]. Insights into the mode of
action of honey for S. aureus, P. aeruginosa and MRSA have been
made [12–14].
Recently synergistic action between piperacillin and methylgly-
oxal (an antibacterial component characteristically found in
manuka honey) was demonstrated by disc diffusion and chequer-
board experiments against MDR clinical isolates of P. aeruginosa
[15]. Synergistic combinations of methylglyoxal with carbenicillin
and with amikacin were also noted against P. aeruginosa.
Furthermore, synergy between oxacillin and manuka honey in
the inhibition of MRSA has been reported [16]. Manuka honey,
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therefore, seems to offer real potential in providing novel
synergistic combinations with antibiotics for treating wound
infections of MDR bacteria. In this study a selection of antibiotics
which affect a wide variety of cellular target sites was tested for
synergistic activity with medical grade manuka honey in order to





Epidemic methicillin resistant Staphylococcus aureus EMRSA-15
(NCTC 13142) and Pseudomonas aeruginosa (NCIMB 8626) were
used throughout this study.
Inhibitors Used in the Study
Fifteen antibiotics were tested: amoxicillin, penicillin G,
cephalexin, ceftizoxime, colistin, erythromycin, gentamicin, imi-
penem, kanamycin, mupirocin, piperacillin/tazobactam, cipro-
floxacin, rifampicin, tetracycline and vancomycin. Antibiotic
Table 1. Susceptibility of EMRSA-15 to honey and antibiotics alone and in combination.
Antibiotic Test method MIC (mg/ml) antibiotic MIC (% w/v) MH* FIC antibiotic FIC MH FICI
alone with MH* alone With antibiotic
Rifampicin Broth dilution 0.0156 0.0156 6 NT 1 – –
Chequerboard NT NT NT NT – – –
E strip 0.004 ,0.002 NT NT ,0.5 – –
Growth curve NT NT NT NT NT – –
Tetracycline Broth dilution 0.5 0.0312 6 NT ,0.5 – –
Chequerboard 1.0 0.125 6 2 0.125 0.33 ,0.5
E strip 1.0 0.0312 NT NT ,0.5 – –
Growth curve 0.5 0.125 6 NT ,0.5 – –
Imipenem Broth dilution 16 .05 6 NT ,0.5 – –
Chequerboard 8 0.0625 6 3 0.0078 0.5 0.5
E strip 4 0.0312 NT NT ,0.5 – –
Growth curve 8 0.25 6 NT ,0.5 – –
Mupirocin Broth dilution 0.06 0.0078 6 NT ,0.5 – –
Chequerboard 0.125 0.0078 6 2 0.06 0.33 ,0.05
E strip ,0.06 ,0.06 NT NT NT – –
Growth curve 0.06 0.0078 6 NT ,0.5 – –
*MH = manuka honey; 5%(w/v) was used in synergy tests.
doi:10.1371/journal.pone.0045600.t001
Table 2. Susceptibility of Pseudomonas aeruginosa to honey and antibiotics alone and in combination.






Rifampicin Broth dilution 8 4 6 NT 0.5 – –
Chequerboard 8 4 7 3 0.5 0.4 0.9
E strip 10 3.5 NT NT ,0.5 – –
Growth curve 8 4 6 NT 0.5 – –
Tetracycline Broth dilution 32 16 6 NT 0.5 – –
Chequerboard 16 8 7 1 0.5 0.1 0.6
E strip 32 8 NT NT ,0.5 – –
Growth curve 8 4 6 NT 0.5 – –
Colistin Broth dilution 2 0.5 6 NT ,0.5 – –
Chequerboard 4 2 7 2 0.5 0.3 0.8
E strip 2 0.4 NT NT ,0.5 – –
Growth curve 2 0.5 6 NT ,0.5 – –
*MH = manuka honey; 5%(w/v) was used in synergy tests.
doi:10.1371/journal.pone.0045600.t002
Synergy between Manuka Honey and Antibiotics
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impregnated susceptibility testing discs were purchased from
Oxoid (Cambridge, UK) and, except for piperacillin/tazobactam,
antibiotics in powdered form were purchased from Sigma (Dorset,
UK). Colistin was tested against only P. aeruginosa and mupirocin
was tested against only MRSA. The manuka honey used in the
study was Manukacare 18+ and it was provided by Comvita, UK.
Antibiotic Sensitivity Testing (AST)
Antibiotic susceptibility was determined using disc diffusion
according to the guidelines published by the British Society for
Antimicrobial Chemotherapy (BSAC), except that Mueller-Hinton
agar (MHA; Oxoid, Cambridge, UK) was used in place of
isosensitest agar [17].
Determination of Minimum Inhibitory Concentration
(MIC)
The MIC of each antibiotic was determined by serial doubling
dilution with Mueller Hinton Broth (MHB; Oxoid, Cambridge,
UK) in microtitre plates. The MIC of manuka honey was also
determined in microtitre plates by dilution in MHB, except that
dilutions varied by 1% (w/v) intervals, instead of doubling
dilutions. Microtitre plates were inoculated with approximate-
ly105 cfu/mL and incubated at 37uC for 24 h. The lowest
concentration to prevent visible growth was recorded as the
MIC. MICs of antibiotics were also determined with E-strips
(bioMe´rieux, Basingstoke, UK) using lawn plates of test bacteria
on MHA, according to the manufacturer’s instructions.
Testing for Synergistic Antibiotic and Honey
Combinations by AST
To screen for antibiotic and honey combinations with potential
synergistic activity, disc diffusion tests were repeated with MHA
containing 5% (w/v) manuka honey. This sub-lethal honey
concentration was 1% (w/v) below the MIC of manuka honey.
Antibiotics demonstrating increased zones of inhibition were
further investigated, but combinations without were not.
Testing for Synergistic Antibiotic and Honey
Combinations by MIC
Similarly MICs of antibiotics were repeated by serial doubling
dilution in MHB containing 5% (w/v) manuka honey. MICs were
also determined in microtitre plates by chequerboard dilution
where serial doubling dilutions of the antibiotic and serial doubling
dilutions of manuka honey in MHB were prepared. Microtitre
plates were inoculated with approximately105 cfu/mL and incu-
bated at 37uC for 24 h.
Testing for Synergistic Antibiotic and Honey
Combinations by E Strips
The MIC of each antibiotic was confirmed by E strips and
MHA containing 5% (w/v) manuka honey.
Figure 1. Antibiotic sensitivity testing of EMRSA-15 by disc diffusion. Diameters of zones of inhibition of antibiotics (mm) against EMRSA-15
on plates of Mueller Hinton agar without (grey bars) and with (black bars) 5% (w/v) manuka honey.
doi:10.1371/journal.pone.0045600.g001
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Figure 2. Antibiotic sensitivity testing of Pseudomonas aeruginosa by disc diffusion. Diameters of zones of inhibition of antibiotics (mm)
against P.aeruginosa on plates of Mueller Hinton agar without (grey bars) and with (black bars ) 5% (w/v) manuka honey.
doi:10.1371/journal.pone.0045600.g002
Figure 3. Sensitivity of EMRSA-15 to imipenem by E strip testing. a) MIC of 4 mg/ml imipenem was seen on Mueller Hinton agar. b) MIC of
0.032 mg/ml imipenem was seen on Mueller Hinton agar containing 5% (w/v) manuka honey.
doi:10.1371/journal.pone.0045600.g003
Synergy between Manuka Honey and Antibiotics
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Testing for Synergistic Antibiotic and Honey
Combinations by Growth Curves
The lowest concentration of an antibiotic needed to prevent the
growth of a test organism in the presence and absence of 5% (w/v)
manuka honey was determined by monitoring optical density at
550 nm at hourly intervals over 23 h in microtitre plates incubated
at 37uC in a Tecan Infinite plate reader. Doubling dilutions of
antibiotic were tested in MHB with and without 5% (w/v) manuka
honey.
All experiments were performed on three occasions.
For each method used, the fractional inhibition concentration
(FIC) was calculated for each antibiotic, where FIC = MIC of the
antibiotic used in combination with manuka honey divided by its
MIC alone. Also FIC of honey was calculated from chequerboard
experiments, where FIC = MIC of manuka honey used in
combination with an antibiotic divided by its MIC alone.
Fractional inhibition concentration index (FICI) was calculated
for each combination of antibiotic and manuka honey tested by
chequerboard. FICI = FIC of an antibiotic + FIC of manuka
honey. The results were interpreted as follows: #0.5– synergy;
.0.5 to #4– additivity and .4 - antagonism.
Results
The MIC of manuka honey against MRSA was found to be 6%
(w/v) in serial broth dilutions, chequerboards and growth curves
(Table 1) and 6, 7 and 6% (w/v), respectively, against P. aeruginosa
(Tables 1 and 2). Therefore 5% (w/v) manuka honey was used in
testing for synergistic combinations. Determining antibiotic
susceptibility by disc diffusion showed that several antibiotics
exhibited increased sensitivity in the presence of manuka honey
and allowed for any antibiotics without increased activity to be
discarded at this point. Initially the most effective combinations
against EMRSA-15 were observed to be piperacillin/tazobactam,
rifampicin, tetracycline, imipenem and mupircoin (Fig. 1). Against
P. aeruginosa rifampicin, tetracycline and colistin showed augment-
ed activity in the presence of honey (Fig. 2). E strips provided a
confirmation of these effects (selected examples are shown in Fig. 3
and 4), but the susceptibility of MRSA to rifampicin without honey
made it difficult to perceive increased susceptibility in the presence
of honey. Also it was decided not to test the piperacillin/
tazobactam combination further but to concentrate on single
antibiotics.
Determining MICs by broth dilution with and without manuka
honey showed that activity of rifampicin against MRSA was not
enhanced and this antibiotic was not investigated further with this
bacterium. MICs of the remaining antibiotics determined with and
without manuka honey by broth dilution, yielded FICs #0.5 in
every case (Table 1 and 2), which suggested synergy. These were
confirmed by chequerboard experiments and FICIs were calcu-
lated to be less than 1.0.
The effect of manuka honey in potentiating antibiotic activity
was best illustrated by growth curves where concentrations of
antibiotics significantly below their MICs values inhibited growth
of test organisms in the presence of sublethal concentrations of
manuka honey (Fig. 5 and 6). Synergistic activity between manuka
honey and each of tetracycline, imipenem and mupirocin were
discovered for MRSA, and additivity between each of rifampicin,
tetracycline and colistin and manuka honey for P. aeruginosa.
Discussion
Infections with Staphylococcus or Pseudomonas species are notori-
ously difficult to treat as both organisms exhibit resistance to
multiple antibiotics, yet few new antibiotics are currently in
development [18,19]. It has been shown that combinations of
antibiotics with non antibiotic substances can enhance the efficacy
of a number of currently used antibiotics by forming syncretic
combinations [20,21]. Many natural compounds have previously
been shown to have potential to inhibit antibiotic resistance in
bacteria [22].
In this study, three antibiotics, from an initial selection of fifteen
antibiotics proved to be synergistic in combination with sublethal
levels of manuka honey against MRSA and three were additive
against P. aeruginosa. One combination (manuka honey and
tetracycline) exhibited enhanced activity against both of the test
bacteria, suggesting that it may be the best combination for further
investigation. Wounds tend to support diverse polymicrobial
communities. Since tetracycline has a broad spectrum of activity,
Figure 4. Sensitivity of Pseudomonas aeruginosa to tetracycline by E strip testing. a) MIC of 32 mg/ml tetracycline was seen on Mueller
Hinton agar. b) MIC of 8 mg/ml tetracycline was seen on Mueller Hinton agar containing 5% (w/v) manuka honey.
doi:10.1371/journal.pone.0045600.g004
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Figure 5. Effect of antibiotics, manuka honey singly and in combination on the growth of EMRSA-15. EMRSA-15 was cultivated in
microtitre plates in Mueller Hinton agar with a range of concentrations of antibiotic with and without 5% (w/v) manuka honey and optical density at
550 nm monitored with time. Only the lowest concentration of antibiotic to allow growth is shown in each experiment. MHB=Mueller Hinton broth;
MH=MHB with 5% (w/v) manuka honey; in a) T = tetracycline; in b) I = imipenem; in c) M=mupirocin.
doi:10.1371/journal.pone.0045600.g005
Synergy between Manuka Honey and Antibiotics
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Figure 6. Effect of antibiotics, manuka honey singly and in combination on the growth of Pseudomonas aeruginosa. P. aeruginosa was
cultivated in microtitre plates in Mueller Hinton agar with a range of concentrations of antibiotic with and without 5% (w/v) manuka honey and
optical density at 550 nm monitored with time. Only the lowest concentration of antibiotic to allow growth is shown in each experiment.
MHB=Mueller Hinton broth; MH=MHB with 5% (w/v) manuka honey; in a) R = rifampicin; in b) T = tetracycline; in c) C = colistin.
doi:10.1371/journal.pone.0045600.g006
Synergy between Manuka Honey and Antibiotics
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it would be interesting to determine whether synergistic effects are
seen with a wider range of wound pathogens.
Several different methods were used in this study to ensure that
putative synergistic combinations were confirmed, as it has been
noted that different methods may give differing results. This was
seen here in the case of rifampicin and honey against MRSA. The
initial observations with antibiotic sensitivity discs and E-strips
indicated synergy; however this did not translate across to the
other tests and broth dilutions gave no change in MICs (Table 1).
Although it is worth noting that for all other combinations tested
here, the decrease in MIC of antibiotic when combined with
manuka honey recorded by broth dilutions was consistent across
the other methods used here.
Imipenem and manuka honey were found to be synergistic towards
MRSA (Table 1), but not towards P. aeruginosa (Fig. 1). Although this
observation would exclude this particular combination from being
considered for topical use in wounds generally, it is still conceivable that
it might play a role in the removal of MRSA from colonised wounds
and other body sites. Mupirocin is already used in this context, so
improving its efficacy by adding low concentrations of manuka honey is
feasible. It may also help to overcome mupirocin resistance in
staphylococci and is worthy of continued investigation.
Colistin can be expected to have little effect on Gram positive
bacteria and nephrotoxicity limits its systemic use against Gram
negative infections. Finding that its activity was enhanced by
manuka honey suggests that it might be used topically in treating
wounds with persistent Gram negative infections and this
observation warrants further research.
Although two research groups have reported synergy between
gentamicin and honey [7,8], this was not replicated here with
manuka honey. This could be due to differences in composition of
honey. It is likely that the botanical origin of honey influences its
biological activity because different antibacterial components have
been identified in different honey samples [23]. This makes it
important to select an appropriate honey for clinical use.
The use of antibiotics exerts selection pressures that favour the
emergence of mutants with antibiotic resistance determinants. Training
experiments withmanuka honey indicate that bacteria failed tomanifest
resistance to honey in the laboratory. [24,25]. It can be postulated that
combinations of antibiotic and honey would be less likely to encourage
the emergence of MRD bacteria than antibiotics alone.
Modern wound care dressings that contain manuka honey
normally use either undiluted honey or at least 80% honey by
weight, but the tests employed to demonstrate synergy with
antibiotics here employed a sublethal concentration of (5% w/v).
Manuka honey is produced in New Zealand and the increased
clinical use within the past ten years has called for an increased
supply of medical grade manuka honey. With the well publicised
bee colony losses globally, it is possible that the supply of manuka
honey will not meet clinical demand in the future, so using low
concentrations of honey in topical treatments that also contain
antibiotics could provide a way of using it most effectively to
prolong supply. Since manuka honey is already used in licensed
wound dressings and the antibiotics used here are also regulated
medical products, regulatory barriers to introducing a new product
containing honey and antibiotics might be relatively easily
overcome. However changing attitudes to clinical practice might
take longer because objective clinical evidence will be required.
It is interesting to note that the antibiotics that have shown
synergy with manuka honey in this study are from different
antibiotic classes, which inhibit distinct targets such as the 30 S
ribosome, RNA polymerase, membranes and penicillin binding
proteins (Table 3). This supports the idea that honey is a complex
substance perhaps with multiple active components that affect
more than one cellular target site.
Further investigation will be needed to confirm whether the
combinations identified here are effective against clinical isolates
and biofilms. This information will influence whether they are
taken forward to be developed for clinical use. There are also other
antibiotics that could be tested with manuka honey to discover
even more synergistic combinations.
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